Document:

EX-10.1

 Exhibit 10.1 

 
 

 
  

	To:	Horizon Pharma AG 

Kägenstrasse 17 
 CH-4153 Reinach 
 Switzerland 

Mundipharma Medical Company 
 Mundipharma House, 5th Floor 
 14 Par-la-Ville Road 

PO Box HM 2332 

Hamilton, HM JX Bermuda 
 17th October 2012 
 Dear Sirs 
 Please sign where indicated below to accept the following amendment to the Second Letter Agreement dated 6th October 2011 between Mundipharma International Corporation Limited, Mundipharma Medical
Company and Horizon Pharma AG. 
 PMR Study 
 Mundipharma’s requirement to initiate dosing of first patient in the PMR Study as set out in the First Letter Agreement between the parties shall be amended to “initiate submission for
regulatory and ethics approval prior to
December 31st, 2012”. 

 

									
	 Yours faithfully

Mundipharma International Corporation Limited
	  		  		  	
					
	By:	  	 /s/ Douglas Docherty
	  		  		  	
					
	Name:	  	 Douglas Docherty
	  		  		  	
					
	Title:	  	 General Manager
	  		  		  	

 Agreed to and accepted as of the date first set forth above: 

 

									
	Horizon Pharma AG	  		  	Horizon Pharma AG
					
	By:	 	 /s/ Timothy P. Walbert
	  		  	By:	  	 /s/ Robert W. Metz

					
	Name:	 	 Timothy P. Walbert
	  		  	Name:	  	 Robert W. Metz

					
	Title:	 	 Chairman, President, CEO
	  		  	Title:	  	 SVP Global Business Ops, Chief Compliance Officer

  

									
	Mundipharma Medical Company	  		  		  	
					
	By:	  	 /s/ Douglas Docherty
	  		  		  	
					
	Name:	  	 Douglas Docherty
	  		  		  	
					
	Title:	  	 General Manager
	  		  		  	

 MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED 

Mundipharma House -14, Par-la-Ville Road - P.O. Box HM 2332 - Hamilton HM JX -Bermuda 

Tel: (441) 295-6480 - Fax: (441) 292-1472 
 a member of the Mundipharma International GroupEX-10.2

 Exhibit 10.2 
 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. 
 Confidential Treatment Requested Under 
 17 C.F.R. Sections
200.80(b)(4) and 240.24b-2 
  

							
	  
  
	  	

	  	  
  

	To:	 	  Horizon Pharma AG	  	  	
		 	  Kägenstrasse 17	  	  	

 CH-4153 Reinach 
 Switzerland 
 Mundipharma Medical Company 

Mundipharma House, 5th Floor 
 14 Par-la-Ville Road 
 PO Box HM 2332 

Hamilton, HM JX 

Bermuda 

21st March, 2013 
 Dear Sirs

 Exclusive Distribution Agreement, dated March 24, 2009 (as amended, the “EDA”) between Horizon Pharma AG (previously Nitec
Pharma AG) and Mundipharma International Corporation Limited (“MICL”); the Manufacturing and Supply Agreement, dated March 24, 2009 (as amended, the “MSA”) between Horizon Pharma AG and Mundipharma Medical Company
(“MMCo”); Letter Agreement, dated March 2, 2011, by and among MICL, MMCo, Horizon Pharma AG and Horizon Pharma GmbH (“First Letter Agreement”); and Second Letter Agreement, dated October 6, 2011, by and among MICL,
MMCo, Horizon Pharma AG and Horizon Pharma GmbH (“Second Letter Agreement”, and together with the EDA, MSA, and First Letter Agreement, the “Agreements”) 
 Please sign where indicated below to indicate your consent to the following amendment. Capitalised terms used but not defined herein shall be as defined in the EDA. 

 

	 	1.	Milestone payments payable to the Principal by the Distributor as set out in Schedule 5 of the EDA on [*...***...] or [...***...] shall only be payable by
the Distributor on [...***...] shall not trigger such milestone payment [...***...]. Should [...***...], the milestone payments set forth above for [...***...] shall become payable upon [...***...].

  

	 	2.	Should Mundipharma sell the Product [...***...], it shall order the Product in accordance with the terms of the MSA, but in minimum order sizes of
[...***...] packs per SKU. This provision shall come to an end upon payment of the milestones for [...***...] referred to in paragraph (1) above, at which point the provisions of this paragraph (2) shall no longer apply.

 This letter agreement shall be governed and construed under Swiss law. Except as amended above, the Agreements shall remain in
full force and effect in accordance with their terms. This letter agreement may be signed in counterparts, each of which shall be deemed an original, and all of which taken together shall constitute one instrument. 

 
 * ***Confidential
Treatment Requested 
 MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED 

Mundipharma House -14, Par-la-Ville Road - P.O. Box HM 2332 - Hamilton HM JX -Bermuda 

Tel: (441) 295-6480 - Fax: (441) 292-1472 
 a member of the Mundipharma International Group 

 Yours faithfully 
 Mundipharma International Corporation Limited 
  

									
	By:	  	 /s/ Douglas Docherty
	  		  		  	
					
	Name:	  	 Douglas Docherty
	  		  		  	
					
	Title:	  	 General Manager
	  		  		  	

 Agreed to and accepted as of the date first set forth above: 

 

									
	HORIZON PHARMA AG	  		  	MUNDIPHARMA MEDICAL COMPANY
					
	By:	  	 /s/ Hans Pater Zobel
	  		  	By:	  	 /s/ Douglas Docherty

					
	Name:	  	 Hans Pater Zobel
	  		  	Name:	  	 Douglas Docherty

					
	Title:	  	 Managing Director Managing Director
	  		  	Title:	  	 General Manager

				
	HORIZON PHARMA AG	  		  		  	
					
	By:	  	 /s/ Robert Metz
	  		  		  	
					
	Name:	  	 Robert Metz
	  		  		  	
					
	Title:	  	 Managing Director
	  		  		  	

  
 3.EX-10.86(o)

 Exhibit 10.86(o) 

EXECUTION VERSION 
 REVOLVING CREDIT COMMITMENT INCREASE SUPPLEMENT 
 March 14, 2013 

Reference is made to the Amended and Restated Credit Agreement, dated as of June 30, 2011 (as amended by the First and Second
Amendments thereto, dated as of May 9, 2012, as further amended by the Third, Fourth and Fifth Amendments thereto, dated as of September 28, 2012, and as supplemented by that Revolving Credit Commitment Increase Supplement dated as of
January 28, 2013, and as further amended, supplemented or modified from time to time, the “Credit Agreement”), among SBA Senior Finance II LLC, a Florida limited liability company (the “Borrower”), the several
banks and other financial institutions or entities from time to time parties thereto (the “Lenders”) and Toronto Dominion (Texas) LLC, as Administrative Agent. Unless otherwise defined herein, terms defined in the Credit Agreement
and used herein shall have the meanings given to them in the Credit Agreement. 
 The Increasing Lender identified on Schedule l
hereto (the “Increasing Lender”), the Administrative Agent and the Borrower agree as follows: 
 1. The
Increasing Lender hereby irrevocably increases its Revolving Credit Commitment(s) to the Borrower by the amount set forth on Schedule 1 hereto (the “Increased Revolving Credit Commitment”) pursuant to Section 2.19(c) of the
Credit Agreement. From and after the Effective Date (as defined below), the Increasing Lender will be a Lender under the Credit Agreement with respect to the Increased Revolving Credit Commitment as well as its existing Revolving Credit
Commitment(s) under the Credit Agreement. 
 2. The Administrative Agent (a) makes no representation or warranty and
assumes no responsibility with respect to any statements, warranties or representations made in or in connection with the Credit Agreement or with respect to the execution, legality, validity, enforceability, genuineness, sufficiency or value of the
Credit Agreement, any other Loan Document or any other instrument or document furnished pursuant thereto; and (b) makes no representation or warranty and assumes no responsibility with respect to the financial condition of the Parent, Holdings,
SBA Senior Finance or the Borrower, any of their respective Subsidiaries or Affiliates or any other obligor or the performance or observance by the Parent, Holdings, SBA Senior Finance or the Borrower, any of their respective Subsidiaries or
Affiliates or any other obligor of any of their respective obligations under the Credit Agreement or any other Loan Document or any other instrument or document furnished pursuant hereto or thereto. 

3. The Increasing Lender (a) represents and warrants that it is legally authorized to enter into this Revolving Credit Commitment
Increase Supplement; (b) confirms that it has received a copy of the Credit Agreement, together with copies of the most recent financial statements delivered pursuant to Section 4.1 of the Credit Agreement and such other documents and
information as it has deemed appropriate to make its own credit analysis and decision to enter into this Revolving Credit Commitment Increase Supplement; (c) agrees that it will, independently and without reliance upon the Administrative Agent
or any other Lender and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Credit Agreement, the

 
other Loan Documents or any other instrument or document furnished pursuant hereto or thereto; (d) appoints and authorizes the Administrative Agent to take such action as agent on its behalf
and to exercise such powers and discretion under the Credit Agreement, the other Loan Documents or any other instrument or document furnished pursuant hereto or thereto as are delegated to the Administrative Agent by the terms thereof, together with
such powers as are incidental thereto; and (e) agrees that it will be bound by the provisions of the Credit Agreement and will perform in accordance with its terms all the obligations which by the terms of the Credit Agreement are required to
be performed by it as a Lender, including, if it is organized under the laws of a jurisdiction outside the United States, its obligation pursuant to Section 2.15 of the Credit Agreement. 

4. The effective date of this Revolving Credit Commitment Increase Supplement shall be the Effective Date of the Increased Revolving
Credit Commitment described in Schedule 1 hereto (the “Effective Date”). Following the execution of this Revolving Credit Commitment Increase Supplement by each of the Increasing Lender and the Borrower, it will be delivered to the
Administrative Agent for acceptance and recording by it pursuant to the Credit Agreement, effective as of the Effective Date (which shall not, unless otherwise agreed to by the Administrative Agent, be earlier than five Business Days after the date
of such acceptance and recording by the Administrative Agent). 
 5. Upon such acceptance and recording, from and after the
Effective Date, the Administrative Agent shall make all payments in respect of the Increased Revolving Credit Commitment (including payments of principal, interest, fees and other amounts) to the Increasing Lender for amounts which have accrued on
and subsequent to the Effective Date. 
 6. From and after the Effective Date, the Increasing Lender shall be a party to the
Credit Agreement and, to the extent provided in this Revolving Credit Commitment Increase Supplement, have the rights and obligations of a Lender thereunder and shall be bound by the provisions thereof. 

7. This Revolving Credit Commitment Increase Supplement shall be governed by and construed in accordance with the laws of the State of
New York. 
 IN WITNESS WHEREOF, the parties hereto have caused this Revolving Credit Commitment Increase Supplement to be
executed as of the date first above written by their respective duly authorized officers on Schedule 1 hereto. 

  
 2 

 Schedule 1 
 to Revolving Credit Commitment Increase Supplement 
 Name of Increasing Lender: Citibank,
N.A. 
 Effective Date of Increased Revolving Credit Commitment: March 28, 2013 

 

							
	Principal
Amount of
Increased Revolving Credit Commitment:	 	  	Total Amount of Revolving Credit
Commitment(s)
of Increasing
Lender
(including Increased Revolving Credit
Commitment):	 
		
	$	40,000,000	  	  	$	115,000,000	  
	  
	  
	 	  	  
	  
	 

 [Signature Pages Follow] 

 Schedule 1 
 to Revolving Credit Commitment Increase Supplement 
  

									
	CITIBANK, N.A.	 		 	SBA SENIOR FINANCE II LLC
					
	By:	 	  
	 		 	By:	 	  

	Name:	 		 		 	Name:	 	
	Title:	 		 		 	Title:	 	
					
	By:	 	  
	 		 		 	
	Name:	 		 		 		 	
	Title:	 		 		 		 	
					
	Accepted:	 		 		 		 	
				
	 TORONTO DOMINION (TEXAS) LLC,
as Administrative Agent
	 		 		 	
					
	By:	 	  
	 		 		 	
	Name:	 		 		 		 	
	Title:	 		 		 		 	
				
	THE TORONTO-DOMINION BANK, NEW YORK BRANCH,	 		 		 	
	 as Issuing Lender
	 		 		 	
					
	By:	 	  
	 		 		 	
	Name:	 		 		 		 	
	Title:	 		 		 		 	

 [Signature Page to Revolving Increase Supplement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}]]